CLEVELAND, March 06, 2023 (GLOBE NEWSWIRE) -- NovelMed Therapeutics announced today that NM3086, the lead clinical asset in its Properdin-associated Alternative Pathway (AP) program, demonstrated ...
CLEVELAND, June 05, 2023 (GLOBE NEWSWIRE) -- NovelMed Therapeutics, Inc. announced today topline results from First-in-Human Phase I clinical trial of its complement blocker monoclonal anti-Properdin ...
Knowledge in immunology has been advanced by recent research. A new paper presents significant new findings about the protein properdin -- an important part of the immune system. It is a positive ...
Novelmed Therapeutics Inc. has reported topline results with its lead anti-properdin antibody NM-3086 in a rabbit model of paroxysmal nocturnal hemoglobinuria (PNH). NM-3086 is a potent, ...
NM5072 is a potential first-in-class monoclonal antibody that selectively blocks properdin, a protein of the complement alternative pathway. The Food and Drug Administration (FDA) has granted Orphan ...
Between vaccine refusal, drug resistant strains of bacteria, and the growing ranks of the immuno-compromised, it sometimes seems that we humans are losing our brief moment of superiority in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results